Zevra Therapeutics (ZVRA) Assets Average (2015 - 2026)

Zevra Therapeutics' Assets Average history runs 12 years deep, the most recent figure standing at $281.7 million for Q1 2026.

• Quarterly Assets Average rose 60.56% year-over-year to $281.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $281.7 million (up 60.56% YoY) and the FY2025 annual result came in at $231.4 million, up 32.07% from the prior year.
• Assets Average was $281.7 million for Q1 2026 at Zevra Therapeutics, up from $277.4 million in the prior quarter.
• Across five years, Assets Average topped out at $281.7 million in Q1 2026 and bottomed at $61.9 million in Q2 2022.
• A 5-year average of $168.0 million and a median of $161.8 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average tumbled 45.98% — and 2026, when it jumped 60.56%.
• Zevra Therapeutics' Assets Average stood at $117.2 million in 2022, then jumped by 32.77% to $155.7 million in 2023, then increased by 18.75% to $184.8 million in 2024, then surged by 50.09% to $277.4 million in 2025, then gained by 1.53% to $281.7 million in 2026.
• Business Quant data shows ZVRA's Assets Average at $281.7 million in Q1 2026, $277.4 million in Q4 2025, and $263.2 million in Q3 2025.